Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Other financing activities (2021 - 2022)

Prime Medicine (PRME) has disclosed Other financing activities for 2 consecutive years, with $1.4 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Other financing activities rose 28.91% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2023, down 62.45%, and an annual FY2022 reading of $4.0 million, up 272.19% over the prior year.
  • Other financing activities was $1.4 million for Q4 2022 at Prime Medicine, up from $746000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.4 million in Q4 2022 and bottomed at $624000.0 in Q2 2022.